drugset / Trial / NCT04564872
HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the efficacy of HSK7653 (as an add-on to metformin) compared with linagliptin after 24 weeks, and the safety (up to 52 weeks) of HSK7653 in Chinese patients with Type 2 Diabetes who have inadequate glycemic control on diet/exercise therapy and metformin agent monotherapy.
Timeline
- Start
- 2020-11-13
- Primary completion
- 2022-01-21
- Completion
- 2022-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK7653 | Unknown | 10 mg | Oral |
| Subject | HSK7653 | Unknown | 25 mg | Oral |
| Comparator | Linagliptin | Small molecule | 5 mg | Oral |